Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Transition Therapeutics licenses Islet Neogenesis Therapy to Novo Nordisk

Aug. 25, 2004

New LXR modulators designed by researchers at X-Ceptor and Sankyo

Aug. 25, 2004

New cannabinoid CB1 antagonist for use in obesity, cognitive disorders, etc.

Aug. 24, 2004

New antiobesity agents disclosed by Bayer in a recent patent

Aug. 24, 2004

New antidiabetic agents in early development at Bayer

Aug. 24, 2004

Novel SGLT2 inhibitors prepared and tested at Kissei

Aug. 24, 2004

Eisai presents novel SERM derivatives

Aug. 23, 2004

Role of oleamide and anandamide in food intake and sexual behavior in rats

Aug. 23, 2004

Improved histamine H3 antagonists/inverse agonists presented by Abbott

Aug. 18, 2004

AMG-162 pivotal study triggers milestone payment to Abgenix

Aug. 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...